all
Item
documented acute lymphoblastic leukemia (l1 or l2 subtypes)
boolean
C0023449 (UMLS CUI [1])
first or subsequent relapse
Item
first or subsequent relapse
boolean
C0277556 (UMLS CUI [1])
age
Item
365 days of age or older
boolean
C0001779 (UMLS CUI [1])
chemotherapy or immunotherapy
Item
greater than 7 days from any chemotherapy or immunotherapy, with the exception of intrathecal chemotherapy
boolean
C0392920 (UMLS CUI [1])
C0021083 (UMLS CUI [2])
blast count
Item
absolute peripheral leukemia blast count of 1000 cells/ul or greater
boolean
C0427541 (UMLS CUI [1])
informed consent
Item
patient (or parent/guardian if patient is less than 18 years of age) must sign informed consent
boolean
C0021430 (UMLS CUI [1])
acute lymphoblastic leukemia l3 subtype
Item
burkitts leukemia (acute lymphoblastic leukemia l3 subtype)
boolean
C0279582 (UMLS CUI [1])
active infection
Item
uncontrolled active infection
boolean
C0009450 (UMLS CUI [1])
pregnant or breastfeeding
Item
pregnancy or mothers who are nursing
boolean
C0549206 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
rapamycin
Item
patient currently taking rapamycin
boolean
C0072980 (UMLS CUI [1])
C2347852 (UMLS CUI [2])
liver dysfunction
Item
patients with significant liver dysfunction as outlined in protocol
boolean
C0086565 (UMLS CUI [1])
severe concurrent disease
Item
severe concurrent disease, which in the judgment of the investigator, would make the patient inappropriate for entry into the study
boolean
C1321605 (UMLS CUI [1])
C0439801 (UMLS CUI [2])
C0009488 (UMLS CUI [3])
active psychiatric disease, substance abuse, or mental illness
Item
active psychiatric disease, substance abuse, or mental illness that would interfere with cooperation with the requirements of the trial
boolean
C0021430 (UMLS CUI [1])
C0439801 (UMLS CUI [2])
C0009488 (UMLS CUI [3])